Veru Inc. (VERU) reported fiscal 2026 third quarter results for the period ended June 30, 2026, with a net loss of $7.0 million, or $0.30 per basic and diluted share. The company said its Phase 2b PLATEAU clinical trial of enobosarm and semaglutide for high quality weight loss is fully enrolled with 239 patients.
Veru said interim analysis results from PLATEAU remain on track for the first quarter of calendar 2027, with final topline clinical data expected in the fourth quarter of calendar 2027. The company also cited a June 2026 clinical supply agreement with Novo Nordisk and an August 2026 USPTO notice of allowance for a key U.S. patent.
- Research and development expenses were $4.4 million, up from $3.0 million a year earlier.
- General and administrative expenses were $3.4 million, down from $5.0 million a year earlier.
- Operating loss from continuing operations was $7.7 million, compared with $7.5 million a year earlier.
- Cash, cash equivalents and restricted cash were $23.9 million as of June 30, 2026.
- The pending U.S. patent, when issued, is expected to provide protection until at least October 2044.
$VERU Hedge Fund Activity
We have seen 17 institutional investors add shares of $VERU stock to their portfolio, and 23 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FNY INVESTMENT ADVISERS, LLC added 105,081 shares (+inf%) to their portfolio in Q2 2026, for an estimated $328,903
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 100,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $221,000
- RENAISSANCE TECHNOLOGIES LLC added 69,250 shares (+inf%) to their portfolio in Q1 2026, for an estimated $153,042
- CITADEL ADVISORS LLC removed 68,080 shares (-60.5%) from their portfolio in Q1 2026, for an estimated $150,456
- BLACKROCK, INC. added 52,915 shares (+46.3%) to their portfolio in Q2 2026, for an estimated $165,623
- JANE STREET GROUP, LLC removed 48,860 shares (-68.2%) from their portfolio in Q1 2026, for an estimated $107,980
- GSA CAPITAL PARTNERS LLP removed 38,360 shares (-19.6%) from their portfolio in Q2 2026, for an estimated $120,066
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
